Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.
LivaNova PLC (NASDAQ: LIVN) is a global medical technology company headquartered in London, focused on select neurological and cardiac conditions. This news page aggregates company announcements, clinical updates, investor communications, and other disclosures that LivaNova issues through press releases and related channels.
Readers can find coverage of LivaNova’s neuromodulation activities, including developments in VNS Therapy for Drug‑Resistant Epilepsy and results from the CORE‑VNS real‑world study. News items also describe health economics analyses, reimbursement decisions affecting VNS Therapy procedures under U.S. Medicare programs, and scientific presentations at major epilepsy meetings.
The feed also includes updates on LivaNova’s cardiopulmonary business and its heart‑lung support technologies, as well as information on its work in obstructive sleep apnea through proximal hypoglossal nerve stimulation and the aura6000 investigational system. Articles may highlight data from randomized controlled trials, long‑term follow‑up analyses, and presentations at specialized surgical sleep and medical conferences.
In addition, investors can follow LivaNova’s participation in healthcare investment conferences, Investor Day events, and quarterly financial result announcements, which the company often distributes via press release and webcasts. By reviewing this page, users can track how LivaNova communicates about its core Epilepsy and Cardiopulmonary businesses, its research programs, and its long‑range strategic plans.
For anyone researching LIVN stock or monitoring developments in medical technology for neurological and cardiac conditions, this news page offers a centralized view of LivaNova’s public announcements over time.
LivaNova PLC (NASDAQ: LIVN) announced its participation in the American Epilepsy Society 2022 Annual Meeting, taking place from December 2-6 in Nashville, Tennessee. The company will showcase seven scientific posters focused on advancing neuromodulation and improving treatment for drug-resistant epilepsy. Dr. Bryan Olin emphasized the company's commitment to enhancing patients' quality of life. Attendees will have the opportunity to engage with presenters about the research findings.
LivaNova PLC (NASDAQ: LIVN) has received 510(k) clearance from the FDA for its LifeSPARC system, enhancing access to extracorporeal membrane oxygenation (ECMO) for hospitals. This new clearance allows ECMO use beyond six hours for patients in acute respiratory or cardiopulmonary failure, including those affected by COVID-19. LifeSPARC aims to simplify ECMO with a user-friendly design, making it suitable for healthcare facilities of all sizes. The company has a strong track record of 100% customer response to recent updates following a recall.
LivaNova PLC (NASDAQ: LIVN) announces that its CEO, Damien McDonald, will present a business update at three healthcare conferences in New York this month. The conferences include the Stifel Healthcare Conference on November 15, the Wolfe Research Healthcare Conference on November 16, and the Piper Sandler Healthcare Conference on November 29. The Stifel and Piper events will be streamed live, with recordings available afterward, while the Wolfe conference will not be available for streaming. For more details, visit www.livanova.com/events.
LivaNova PLC (Nasdaq: LIVN) reported a third-quarter 2022 revenue of $252.6 million, a 0.2% decline on a reported basis but 5.2% growth on a constant-currency basis compared to the prior year. A U.S. GAAP diluted loss per share reached $2.01, impacted by a non-cash goodwill impairment charge. Neuromodulation revenue increased by 10.4%, while Cardiopulmonary grew by 6.6%. Advanced Circulatory Support faced a significant 43.8% decline. The company maintains its full-year 2022 revenue growth outlook between 4% and 6% on a constant-currency basis.
LivaNova PLC (NASDAQ: LIVN) will hold a conference call on November 2, 2022, at 12 p.m. London time (8 a.m. EDT) to discuss its third-quarter 2022 results, releasing the details prior to the call. Interested participants can access a live audiocast at www.livanova.com/events. Call-in options are also available for both U.S. and international listeners. A replay will be offered for 90 days post-call. LivaNova is headquartered in London, employing approximately 3,000 people globally, focusing on innovative medical technologies for patients.
LivaNova PLC (NASDAQ: LIVN) announced the appointment of Brooke Story to its Board of Directors, effective September 15, 2022. Story brings over 20 years of experience in medical technology, currently serving as Worldwide President, Integrated Diagnostic Solutions at BD (NYSE: BDX). She previously held leadership roles at Medtronic, enhancing her expertise in the industry. The Board's Chair, William Kozy, emphasized Story's capability in fostering talent and delivering economic value, which is expected to support LivaNova's growth and innovation strategies.
LivaNova PLC (Nasdaq: LIVN) reported a 3.9% decline in revenue, totaling $254.2 million for Q2 2022, though constant-currency revenue increased by 0.5%. Excluding the divested Heart Valves business, revenue grew by 1.8% on a reported basis and 6.5% in constant-currency terms. The diluted earnings per share was $0.30, with adjusted diluted EPS at $0.53. The company anticipates a 4-6% revenue growth for full-year 2022 before currency impacts, while foreign exchange is expected to create a 4-5% headwind. Full-year adjusted EPS is projected between $2.25 and $2.45.
LivaNova PLC (NASDAQ: LIVN) will hold a conference call on August 3, 2022, at 1 p.m. London time (8 a.m. EDT) to discuss its second-quarter 2022 results. The results will be released prior to the call. Interested parties can access a live audiocast on the LivaNova website and also participate via telephone using the specified dialing numbers. A replay will be available for 90 days post-call. LivaNova is a global medical technology company committed to innovative solutions for patients worldwide.
LivaNova PLC (NASDAQ: LIVN) announced that Peter Wilver has joined its Board of Directors, effective immediately, following the company's 2022 AGM on June 13. Wilver brings over 30 years of experience, having previously held significant roles at Thermo Fisher Scientific, Honeywell, and General Electric. His expertise in strategic planning and financial operations is expected to enhance the Board's oversight. Alongside Wilver, eight current directors were re-elected, solidifying leadership continuity within the organization.
LivaNova PLC (Nasdaq: LIVN) announced that CEO Damien McDonald will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15 at 10 a.m. Pacific Time in Rancho Palos Verdes, California. The presentation will be available via webcast for registered participants. Interested individuals should log on 10 minutes early for setup. A replay will be accessible on www.livanova.com within 24 hours for 30 days post-event.
LivaNova is dedicated to innovative medical technologies, employing about 3,000 staff globally.
FAQ
What is the current stock price of Livanova Plc (LIVN)?
What is the market cap of Livanova Plc (LIVN)?
